公司研发进展 - 与多伦多合同研究组织Nucro-Technics Inc合作启动临床前和分析开发服务 [1] - 启动研究性新药(IND)支持计划的首阶段实验室工作 重点开发验证先进分析方法 [1] - 分析方法用于测量独家许可的PNKP抑制剂技术在临床前样本和药物制剂中的含量 [1]

VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / Onco-Innovations Limited (CBOE CA:ONCO )(OTCQB:ONNVF )(Frankfurt:W1H) (WKN: A3EKSZ ) (" Onco " or the " Company ") is pleased to announce that Dalton Pharma Services ("Dalton") has commenced activities to manufacture Onco's proprietary nanoparticle formulation, also know as PEO-b-PBz-CL 1 , a key component of the Company's novel drug delivery platform which is designed for use in conjunction with Onco's proprietary Polynucleotide Kinase Phosphatase (PNK ...